LINC00958与肿瘤预后的Meta分析及生物信息学分析-东南大学学报医学版

LINC00958与肿瘤预后的Meta分析及生物信息学分析

单位：1. 东南大学医学院, 江苏南京 210009;
2. 东南大学附属中大医院泌尿外科, 江苏南京 210009

分类号：R730.7

出版年·卷·期（页码）：2021·40·第一期（27-33）

摘要：

目的：验证长链非编码RNA （lncRNA）LINC00958在不同类型肿瘤中的表达以及预后价值。方法：在PubMed、Web of Science、Elsevier、Springer、知网的数据库中进行相关文献检索，检索时间从建库至2020年4月3日。运用Stata 12.0 MP软件，在肿瘤患者的总体生存期（OS）上计算风险比（HR）和相应的95%置信区间（CI）来评估肿瘤患者的预后，分析优势比（OR）和相应的95%CI来评估癌症患者年龄、性别、肿瘤大小、肿瘤分化程度、肿瘤转移的促进或抑制效应。利用GEPIA在线分析数据库分析LINC00958在各类肿瘤组织中的表达情况以及进行生存分析。结果：总计有8项研究，包括1 060例癌症患者纳入本次Meta分析。与LINC00958低表达组相比，LINC00958高表达组患者的OS较短（HR为1.533，95%CI为1.212~1.940，P<0.001）。LINC00958的高表达与肿瘤发生转移有关（OR为2.859，95%CI为1.966~4.156，P<0.001）。结论：LINC00958的高表达与多种肿瘤的不良预后相关，但需要更多的研究做进一步的分析。

Objective: To verify the expression level and prognostic value of long-chain non-coding RNA(lncRNA) LINC00958 in various tumors. Methods: We searched the PubMed, Web of Science, Elsevier, Springer and CNKI (up to April 3, 2020) for literature. In the overall survival rate, hazard ratio (HR) and the 95% CI were calculated to evaluate the prognosis of tumor by Stata 12.0 MP software. The odds ratio (OR) and 95% CI were analyzed to assess the promotion or inhibition effects of patients' age, gender, tumor size, tumor differentiation and metastasis by Stata 12.0 MP software. Moreover, we extracted data for validation of the results in Gene Expression Profiling Interactive Analysis (GEPIA) dataset. Results: A total of 8 studies comprising 1060 cancer patients were included in the final Meta-analysis. High expression of LINC00958 significantly predicted worse overall survival (OS) in various cancers (HR=1.533, 95%CI:1.212-1.940,P<0.001). Meanwhile, LINC00958 expression was correlated with tumor metastasis (OR=2.859, 95% CI:1.966-4.156, P<0.001). Conclusion: The present study suggests that up-regulation of LINC00958 is related to poor clinical survival outcomes in multiple tumors, but more relevant studies need to be included for further studies.

参考文献：

[1] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
[2] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[3] FENG R M,ZONG Y N,CAO S M,et al.Current cancer situation in China:good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun (Lond),2019,39(1):22.
[4] SAYLES L C,BREESE M R,KOEHNE A L,et al.Genome-informed targeted therapy for osteosarcoma[J].Cancer Discov,2019,9(1):46-63.
[5] WEI S C,DUFFY C R,ALLISON J P.Fundamental mechanisms of immune checkpoint blockade therapy[J].Cancer Discov,2018,8(9):1069-1086.
[6] DESANTIS C E,LIN C C,MARIOTTO A B,et al.Cancer treatment and survivorship statistics,2014[J].CA Cancer J Clin,2014,64(4):252-271.
[7] YARMISHYN A A,KUROCHKIN I V.Long noncoding RNAs:a potential novel class of cancer biomarkers[J].Front Genet,2015,6:145.
[8] WEIDLE U H,BIRZELE F,KOLLMORGEN G,et al.Long non-coding RNAs and their role in metastasis[J].Cancer Genomics Proteomics,2017,14(3):143-160.
[9] PONTING C P,OLIVER P L,REIK W.Evolution and functions of long noncoding RNAs[J].Cell,2009,136(4):629-641.
[10] MERCER T R,DINGER M E,MATTICK J S.Long non-coding RNAs:insights into functions[J].Nat Rev Genet,2009,10(3):155-159.
[11] MATTICK J S,MAKUNIN I V.Non-coding RNA[J].Hum Mol Genet,2006,15(Spec No 1):R17-29.
[12] POLISENO L,SALMENA L,ZHANG J,et al.A coding-independent function of gene and pseudogene mRNAs regulates tumour biology[J].Nature,2010,465(7301):1033-1038.
[13] GUTSCHNER T,BAAS M,DIEDERICHS S.Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases[J].Genome Res,2011,21(11):1944-1954.
[14] LI T,XIE J,SHEN C,et al.Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma[J].Cancer Res,2015,75(15):3181-3191.
[15] LIANG C,LIU J,GE H,et al.The clinicopathological and prognostic value of long non-coding RNA ZEB1-AS1 in solid tumors:a meta-analysis[J].Clin Chim Acta,2018,484:91-98.
[16] LIANG C,QI Z,GE H,et al.Long non-coding RNA PCAT-1 in human cancers:a meta-analysis[J].Clin Chim Acta,2018,480:47-55.
[17] ZHANG S,QIU D,XIE X,et al.Clinicopathological and prognostic value of SNHG6 in cancers:a systematic review and a meta-analysis[J].BMC Cancer,2020,20(1):343.
[18] SEITZ A K,CHRISTENSEN L L,CHRISTENSEN E,et al.Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer[J].Sci Rep,2017,7(1):395.
[19] GUO E,LIANG C,HE X,et al.Long noncoding RNA LINC00958 accelerates gliomagenesis through regulating miR-203/CDK2[J].DNA Cell Biol,2018,37(5):465-472.
[20] WANG W,SONG Z J,WANG Y,et al.Elevated long non-coding RNA LINC00958 was associated with metastasis and unfavorable prognosis in gastric cancer[J].Eur Rev Med Pharmacol Sci,2019,23(2):598-603.
[21] ZUO X,CHEN Z,GAO W,et al.M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma[J].J Hematol Oncol,2020,13(1):5.
[22] CHEN S,CHEN J Z,ZHANG J Q,et al.Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8[J].Cancer Lett,2019,446:49-61.
[23] WANG L,ZHONG Y,YANG B,et al.LINC00958 facilitates cervical cancer cell proliferation and metastasis by sponging miR-625-5p to upregulate LRRC8E expression[J].J Cell Biochem,2020,121(3):2500-2509.
[24] ZHAO H,ZHENG G H,LI G C,et al.Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer[J].J Cell Physiol,2019,234(12):23349-23359.
[25] CHEN F,LIU M,YU Y,et al.LINC00958 regulated miR-627-5p/YBX2 axis to facilitate cell proliferation and migration in oral squamous cell carcinoma[J].Cancer Biol Ther,2019,20(9):1270-1280.
[26] HUANG S,ZHAN Z,LI L,et al.LINC00958-MYC positive feedback loop modulates resistance of head and neck squamous cell carcinoma cells to chemo-and radiotherapy in vitro[J].Onco Targets Ther,2019,12:5989-6000.
[27] CHEN B J,BYRNE F L,TAKENAKA K,et al.Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer[J].Gynecol Oncol,2017,147(3):654-662.
[28] CHEN M,XU Z,ZHANG Y,et al.LINC00958 promotes the malignancy of nasopharyngeal carcinoma by sponging microRNA-625 and thus upregulating NUAK1[J].Onco Targets Ther,2019,12:9277-9290.
[29] FAN Y H,JI C X,XU B,et al.Long noncoding RNA activated by TGF-β in human cancers:a meta-analysis[J].Clin Chim Acta,2017,468:10-16.
[30] ALTMAN D G,MCSHANE L M,SAUERBREI W,et al.Reporting recommendations for tumor marker prognostic studies (REMARK):explanation and elaboration[J].PLoS Med,2012,9(5):e1001216.
[31] HE W,ZHONG G,JIANG N,et al.Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogensis and lymphatic metastasis[J].J Clin Invest,2018,128(2):861-875.
[32] WANG Z,ZHU X,DONG P,et al.Long noncoding RNA LINC00958 promotes the oral squamous cell carcinoma by sponging miR-185-5p/YWHAZ[J].Life Sci,2020,242:116782.
[33] YANG L,LI L,ZHOU Z,et al.SP1 induced long non-coding RNA LINC00958 overexpression facilitate cell proliferation,migration and invasion in lung adenocarcinoma via mediating miR-625-5p/CPSF7 axis[J].Cancer Cell Int,2020,20:24.
[34] WANG Y,HUANG T,SUN X,et al.Identification of a potential prognostic lncRNA-miRNA-mRNA signature in endometrial cancer based on the competing endogenous RNA network[J].J Cell Biochem,2019,120(11):18845-18853.
[35] KIM J,PIAO H L,KIM B J,et al.Long noncoding RNA MALAT1 suppresses breast cancer metastasis[J].Nat Genet,2018,50(12):1705-1715.
[36] 黄立宁,冷开明,徐艺,等.长链非编码RNA ROR在肿瘤中的表达和作用[J].现代医学,2017,45(12):1865-1870.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录